Johnson & Johnson Gains EMA Submission for Teclistamab Indication Extension After Phase 3 MajesTEC-9 OS Win

Johnson & Johnson's EMA submission for a teclistamab indication extension, backed by Phase 3 MajesTEC-9 data, signals an expanding regulatory and manufacturing footprint for off-the-shelf bispecific antibody platforms in oncology biologics. For QA directors and fill-finish operations leads, the trajectory toward earlier lines of therapy means higher commercial volumes and tighter cold-chain discipline, well ahead of any European approval decision.

The MajesTEC-9 study evaluated teclistamab (TECVAYLI®) against standard-of-care regimens, pomalidomide/bortezomib/dexamethasone (PVd) or carfilzomib/dexamethasone (Kd), in patients with relapsed or refractory multiple myeloma (RRMM) who had received one to three prior lines of therapy. The trial enrolled a heavily pretreated population: 85% were refractory to anti-CD38 monoclonal antibodies and 79% to lenalidomide, with more than 90% refractory to their last line. Teclistamab reduced the risk of disease progression or death by 71% (HR 0.29; 95% CI 0.23–0.38; p<0.0001) and the risk of death by 40% (HR 0.60; 95% CI 0.43–0.83; p=0.002). Nearly two-thirds of patients achieved a complete response or better.

MajesTEC-9 is the second positive Phase 3 study supporting teclistamab in earlier treatment lines, following data presented at ASH 2025 on teclistamab plus daratumumab subcutaneous. The ASCO 2026 presentation (Abstract #7507) was accompanied by simultaneous publication in The New England Journal of Medicine, a combination that typically accelerates payer and regulatory engagement timelines in major markets.

For regulatory affairs leads tracking the EMA review cycle, the submission adds to an already active bispecific antibody dossier workload across European competent authorities. The off-the-shelf format distinguishes teclistamab from autologous CAR-T approaches, removing patient-specific manufacturing constraints, but it introduces its own process validation and sterility assurance demands at commercial scale, particularly as the indicated population broadens from heavily pretreated patients toward first relapse.

The supply-chain read is direct: earlier-line use expands the eligible patient pool substantially, which translates into higher batch demand, more frequent fill-finish scheduling, and cold-chain capacity planning that QA and supply operations teams will need to model against projected approval timelines in Europe and other jurisdictions where submissions may follow.

The EMA review outcome will serve as the first measurable checkpoint for whether MajesTEC-9's survival data are sufficient to support a label that positions teclistamab as a second-line standard of care in RRMM.

Source: GlobeNewswire via Johnson & Johnson press release, May 29, 2026. Data presented as oral session Abstract #7507 at ASCO Annual Meeting 2026, with simultaneous publication in The New England Journal of Medicine.